Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors

Xinyu Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingnan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Tang(Stanford Health Care), Bo Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingyang Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Bei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinmiao Jia(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanlin Zeng(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoxing Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College)
EBioMedicine
October 30, 2024
Cited by 40


Related Papers